{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:27:49Z","timestamp":1793921269538,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA009515"],"award-info":[{"award-number":["T32 CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2024,7,26]]},"DOI":"10.1038\/s41388-024-03089-y","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T13:06:42Z","timestamp":1719320802000},"page":"2421-2430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations"],"prefix":"10.1038","volume":"43","author":[{"given":"Talayeh S.","family":"Ghezelayagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan F.","family":"Kohrn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Krimmel-Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Latorre-Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ray","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enna","family":"Manhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0291-1858","authenticated-orcid":false,"given":"Rosa Ana","family":"Risques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"3089_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3089_CR2","doi-asserted-by":"crossref","unstructured":"Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, et al. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. Int J Gynecol Cancer. 2019;29:346\u201352.","DOI":"10.1136\/ijgc-2018-000087"},{"key":"3089_CR3","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28:3010.","journal-title":"Cell Rep"},{"key":"3089_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ygyno.2020.12.007","volume":"160","author":"TS Ghezelayagh","year":"2021","unstructured":"Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol Oncol. 2021;160:786\u201392.","journal-title":"Gynecol Oncol"},{"key":"3089_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"3089_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329\u201333.","journal-title":"J Clin Oncol"},{"key":"3089_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402\u201316.","journal-title":"JAMA"},{"key":"3089_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.143993","volume":"714","author":"B Li","year":"2019","unstructured":"Li B, Pu K, Ge L, Wu X. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: an updated meta-analysis. Gene. 2019;714:143993.","journal-title":"Gene"},{"key":"3089_CR9","doi-asserted-by":"crossref","unstructured":"Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10:eaap8793.","DOI":"10.1126\/scitranslmed.aap8793"},{"key":"3089_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2019.11.124","volume":"156","author":"JD Krimmel-Morrison","year":"2020","unstructured":"Krimmel-Morrison JD, Ghezelayagh TS, Lian S, Zhang Y, Fredrickson J, Nachmanson D, et al. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. Gynecol Oncol. 2020;156:407\u201314.","journal-title":"Gynecol Oncol"},{"key":"3089_CR11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ijgc-2022-003911","volume":"32","author":"MHD van Bommel","year":"2022","unstructured":"van Bommel MHD, Pijnenborg JMA, van der Putten LJM, Bulten J, Snijders M, Kusters-Vandevelde HVN, et al. Diagnostic accuracy of mutational analysis along the Mullerian tract to detect ovarian cancer. Int J Gynecol Cancer. 2022;32:1568\u201375.","journal-title":"Int J Gynecol Cancer"},{"key":"3089_CR12","doi-asserted-by":"publisher","first-page":"e1007108","DOI":"10.1371\/journal.pgen.1007108","volume":"14","author":"RA Risques","year":"2018","unstructured":"Risques RA, Kennedy SR. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14:e1007108.","journal-title":"PLoS Genet"},{"key":"3089_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41568-021-00335-3","volume":"21","author":"N Kakiuchi","year":"2021","unstructured":"Kakiuchi N, Ogawa S. Clonal expansion in non-cancer tissues. Nat Rev Cancer. 2021;21:239\u201356.","journal-title":"Nat Rev Cancer"},{"key":"3089_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0648-4","volume":"11","author":"I Martincorena","year":"2019","unstructured":"Martincorena I. Somatic mutation and clonal expansions in human tissues. Genome Med. 2019;11:35.","journal-title":"Genome Med"},{"key":"3089_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.trecan.2019.07.007","volume":"5","author":"SR Kennedy","year":"2019","unstructured":"Kennedy SR, Zhang Y, Risques RA. Cancer-associated mutations but no cancer: insights into the early steps of carcinogenesis and implications for early cancer detection. Trends Cancer. 2019;5:531\u201340.","journal-title":"Trends Cancer"},{"key":"3089_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1152\/physrev.00004.2022","volume":"103","author":"MA Evans","year":"2023","unstructured":"Evans MA, Walsh K. Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiol Rev. 2023;103:649\u2013716.","journal-title":"Physiol Rev"},{"key":"3089_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2159-8290.CD-23-1508","volume":"14","author":"Z Rahal","year":"2024","unstructured":"Rahal Z, Scheet P, Kadara H. Somatic mutations in normal tissues: calm before the storm. Cancer Discov. 2024;14:605\u20139.","journal-title":"Cancer Discov"},{"key":"3089_CR18","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109:14508\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3089_CR19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/nprot.2014.170","volume":"9","author":"SR Kennedy","year":"2014","unstructured":"Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH, et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc. 2014;9:2586\u2013606.","journal-title":"Nat Protoc"},{"key":"3089_CR20","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1073\/pnas.1601311113","volume":"113","author":"JD Krimmel","year":"2016","unstructured":"Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci USA. 2016;113:6005\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3089_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.celrep.2019.05.109","volume":"28","author":"JJ Salk","year":"2019","unstructured":"Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, et al. Ultra-sensitive TP53 sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan. Cell Rep. 2019;28:132\u201344.e3.","journal-title":"Cell Rep"},{"key":"3089_CR22","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2767-9764.CRC-22-0314","volume":"2","author":"TS Ghezelayagh","year":"2022","unstructured":"Ghezelayagh TS, Kohrn BF, Fredrickson J, Manhardt E, Radke MR, Katz R, et al. Uterine lavage identifies cancer mutations and increased TP53 somatic mutation burden in individuals with ovarian cancer. Cancer Res Commun. 2022;2:1282\u201392.","journal-title":"Cancer Res Commun"},{"key":"3089_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science. 2023;381:eadg7492.","journal-title":"Science"},{"key":"3089_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/humu.23543","volume":"39","author":"T Tikkanen","year":"2018","unstructured":"Tikkanen T, Leroy B, Fournier JL, Risques RA, Malcikova J, Soussi T. Seshat: a web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. Hum Mutat. 2018;39:925\u201333.","journal-title":"Hum Mutat"},{"key":"3089_CR25","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941\u2013D7.","journal-title":"Nucleic Acids Res"},{"key":"3089_CR26","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.celrep.2018.07.037","volume":"24","author":"K Suda","year":"2018","unstructured":"Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori Y, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777\u201389.","journal-title":"Cell Rep"},{"key":"3089_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","volume":"580","author":"L Moore","year":"2020","unstructured":"Moore L, Leongamornlert D, Coorens THH, Sanders MA, Ellis P, Dentro SC, et al. The mutational landscape of normal human endometrial epithelium. Nature. 2020;580:640\u20136.","journal-title":"Nature"},{"key":"3089_CR28","doi-asserted-by":"publisher","first-page":"24627","DOI":"10.18632\/oncotarget.5685","volume":"6","author":"B Milholland","year":"2015","unstructured":"Milholland B, Auton A, Suh Y, Vijg J. Age-related somatic mutations in the cancer genome. Oncotarget. 2015;6:24627\u201335.","journal-title":"Oncotarget"},{"key":"3089_CR29","doi-asserted-by":"crossref","unstructured":"Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci. 2022;23:12041.","DOI":"10.3390\/ijms231912041"},{"key":"3089_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26615-y","volume":"13","author":"JE Barrett","year":"2022","unstructured":"Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022;13:448.","journal-title":"Nat Commun"},{"key":"3089_CR31","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1158\/1078-0432.CCR-23-1197","volume":"29","author":"DN Buckley","year":"2023","unstructured":"Buckley DN, Lewinger JP, Gooden G, Spillman M, Neuman M, Guo XM, et al. OvaPrint-a cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer. Clin Cancer Res. 2023;29:5196\u2013206.","journal-title":"Clin Cancer Res"},{"key":"3089_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.786154","volume":"12","author":"A Gockley","year":"2022","unstructured":"Gockley A, Pagacz K, Fiascone S, Stawiski K, Holub N, Hasselblatt K, et al. A translational model to improve early detection of epithelial ovarian cancers. Front Oncol. 2022;12:786154.","journal-title":"Front Oncol"},{"key":"3089_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51697-6","volume":"9","author":"NS Arildsen","year":"2019","unstructured":"Arildsen NS, Martin de la Fuente L, Masback A, Malander S, Forslund O, Kannisto P, et al. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. Sci Rep. 2019;9:15506.","journal-title":"Sci Rep"},{"key":"3089_CR34","doi-asserted-by":"publisher","first-page":"167ra4","DOI":"10.1126\/scitranslmed.3004952","volume":"5","author":"I Kinde","year":"2013","unstructured":"Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5:167ra4.","journal-title":"Sci Transl Med"},{"key":"3089_CR35","doi-asserted-by":"crossref","unstructured":"Pasupuleti SK, Ramdas B, Burns SS, Palam LR, Kanumuri R, Kumar R, et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Invest. 2023;133:e163968.","DOI":"10.1172\/JCI163968"},{"key":"3089_CR36","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366:eaan4673.","DOI":"10.1126\/science.aan4673"},{"key":"3089_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/1940-6207.CAPR-22-0469","volume":"16","author":"JK Rane","year":"2023","unstructured":"Rane JK, Frankell AM, Weeden CE, Swanton C. Clonal evolution in healthy and premalignant tissues: implications for early cancer interception strategies. Cancer Prev Res. 2023;16:369\u201378.","journal-title":"Cancer Prev Res"},{"key":"3089_CR38","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1158\/0008-5472.CAN-21-3607","volume":"82","author":"J Matas","year":"2022","unstructured":"Matas J, Kohrn B, Fredrickson J, Carter K, Yu M, Wang T, et al. Colorectal cancer is associated with the presence of cancer driver mutations in normal colon. Cancer Res. 2022;82:1492\u2013502.","journal-title":"Cancer Res"},{"key":"3089_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00070","volume":"7","author":"S Franch-Exposito","year":"2023","unstructured":"Franch-Exposito S, Mehine M, Ptashkin RN, Bolton KL, Bandlamudi C, Srinivasan P, et al. Associations between cancer predisposition mutations and clonal hematopoiesis in patients with solid tumors. JCO Precis Oncol. 2023;7:e2300070.","journal-title":"JCO Precis Oncol"},{"key":"3089_CR40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/1471-0528.14543","volume":"124","author":"F Chen","year":"2017","unstructured":"Chen F, Gaitskell K, Garcia MJ, Albukhari A, Tsaltas J, Ahmed AA. Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review. BJOG. 2017;124:872\u20138.","journal-title":"BJOG"},{"key":"3089_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.hoc.2018.07.013","volume":"32","author":"TR Soong","year":"2018","unstructured":"Soong TR, Dinulescu DM, Xian W, Crum CP. Frontiers in the pathology and pathogenesis of ovarian cancer Cancer Precursors \u201cPrecursor Escape\u201d. Hematol Oncol Clin North Am. 2018;32:915\u201328.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3089_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1940-6207.CAPR-18-0009","volume":"11","author":"K Visvanathan","year":"2018","unstructured":"Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, et al. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prev Res. 2018;11:697\u2013706.","journal-title":"Cancer Prev Res"},{"key":"3089_CR43","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1002\/cncr.25439","volume":"116","author":"BM Norquist","year":"2010","unstructured":"Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010;116:5261\u201371.","journal-title":"Cancer"},{"key":"3089_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.7326\/M18-0737","volume":"169","author":"BL Ebert","year":"2018","unstructured":"Ebert BL, Libby P. Clonal hematopoiesis confers predisposition to both cardiovascular disease and cancer: a newly recognized link between two major killers. Ann Intern Med. 2018;169:116\u20137.","journal-title":"Ann Intern Med"},{"key":"3089_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"3089_CR46","unstructured":"StataCorp. Stata: Release 14. College Station, TX: StataCorp LLC; 2015. p. Statistical Software."},{"key":"3089_CR47","unstructured":"IBM. SPSS Statistics for Windows. 28 ed. Armonk, NY: IBM Corp; 2021."},{"key":"3089_CR48","unstructured":"R Development Core Team. R: A language and environment for statistical computing. 4.3.0 ed. Vienna, Austria: R Foundation for Statistical Computing; 2023."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03089-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03089-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03089-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:20:58Z","timestamp":1722028858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03089-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":48,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2024,7,26]]}},"alternative-id":["3089"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03089-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RAR is a consultant and equity holder at TwinStrand Biosciences Inc. and an equity holder at NanoString Technologies Inc. RAR is named inventor on patents owned by the University of Washington and licensed to TwinStrand Biosciences Inc. RAR received research funding from a joined research grant with TwinStrand Biosciences Inc. and Ovartec GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was approved by the Human Subjects Division at the University of Washington (Institutional Review Board numbers 2872 and 7385) and was carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}